[Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)].

Abstract

Twenty-three cases of hematological malignancies (18 plasma cell neoplasm, 2 leukemia and 2 malignant lymphoma) were treated with recombinant human leukocyte interferon (rIFN-alpha A). Among plasma cell neoplasms, excellent and good responses were obtained in 1 case of IgG myeloma and 1 case of Bence-Jones myeloma respectively and fair response was obtained in 5 other cases. Response rats was 11.4%, or 38.9% if fair response was included. Partial remission was obtained in 1 case of chronic lymphocytic leukemia. In one of 2 cases of acute lymphoblastic leukemia, marked reduction of peripheral leukemia cells was noted. Side effects included fever (65%), malaise (20%), nausea-anorexia (43%), leukopenia (52%) and thrombocytopenia (52%). However, all were not serious and disappeared quickly after discontinuation of rIFN-alpha A.

• Authors: R Ohno, Y Kodera, M Ogura, T Murase, N Emi, M Okumura, Y Morishita, E Nagura, S Minami, Y Morishima
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 11 Issue 12 Pt 1 Pg. 2531-6 (Dec 1984) ISSN: 0385-0684 [Print] Japan
• PMID: 6594973 (Publication Type: English Abstract, Journal Article)

Chemical References

• Interferon Type I

Topics

• Adult
• Aged
• Child
• Female
• Humans
• Interferon Type I (therapeutic use)
• Leukemia, Lymphoid (therapy)
• Lymphoma (therapy)
• Male
• Middle Aged
• Multiple Myeloma (therapy)